Editas Medicine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).

CEO

Gilmore O’Neill

CEOGilmore O’Neill

Employees

246

Employees246

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2013

Founded2013

Employees

246

Employees246

EDIT Key Statistics

Market cap

126.41M

Market cap126.41M

Price-Earnings ratio

-0.50

Price-Earnings ratio-0.50

Dividend yield

—

Dividend yield—

Average volume

1.97M

Average volume1.97M

High today

$1.52

High today$1.52

Low today

$1.35

Low today$1.35

Open price

$1.42

Open price$1.42

Volume

1.61M

Volume1.61M

52 Week high

$6.22

52 Week high$6.22

52 Week low

$0.9101

52 Week low$0.9101

EDIT News

TipRanks 4d

Editas Medicine Unveils Promising Gene Editing Data

Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive underval...

TipRanks 5d

Editas Medicine: Hold Rating Amid Legal Uncertainty and Financial Concerns

In a report released today, Yanan Zhu from Wells Fargo maintained a Hold rating on Editas Medicine (EDIT – Research Report), with a price target of $3.00. Prot...

TipRanks 5d

Editas says U.S. Court of Appeals remands CRISPR patent interference decision

Editas Medicine (EDIT) announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial and Appeal Board’s...

Analyst ratings

47%

of 15 ratings

Buy

40%

Hold

46.7%

Sell

13.3%

People also own

Based on the portfolios of people who own EDIT. This list is generated using Robinhood data, and it’s not a recommendation.

CRISPR

Intellia Therapeutics